Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes (Q46967012)

26 December 2017

title

Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes (English)

1 reference

26 December 2017

author name string

William C Zamboni

1

1 reference

26 December 2017

Ramesh K Ramanathan

2

1 reference

26 December 2017

Howard L McLeod

3

1 reference

26 December 2017

Sridhar Mani

4

1 reference

26 December 2017

Douglas M Potter

5

1 reference

26 December 2017

Sandra Strychor

6

1 reference

26 December 2017

Lauren J Maruca

7

1 reference

26 December 2017

Cristi R King

8

1 reference

26 December 2017

Laura L Jung

9

1 reference

26 December 2017

Robert A Parise

10

1 reference

26 December 2017

Merrill J Egorin

11

1 reference

26 December 2017

Todd A Davis

12

1 reference

26 December 2017

Sharon Marsh

13

1 reference

26 December 2017

publication date

1 September 2006

1 reference

26 December 2017

Investigational New Drugs

published in

1 reference

26 December 2017

volume

24

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

page(s)

393-401

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1007/s10637-006-6335-5

exact match

0 references

cites work

Role reversal for anticancer agents

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-006-6335-5

Phenomenology and scientific progress.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-006-6335-5

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

21 January 2018

1 reference

12 December 2020

A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance

1 reference

12 December 2020

Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents

1 reference

12 December 2020

Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database

1 reference

12 December 2020

Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme

1 reference

12 December 2020

Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors

1 reference

12 December 2020

The clinical development of 9-aminocamptothecin.

1 reference

12 December 2020

Evolution of ATP-binding cassette transporter genes

1 reference

12 December 2020

Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells

1 reference

12 December 2020

Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

1 reference

12 December 2020

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma

1 reference

12 December 2020

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

1 reference

12 December 2020

Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.

1 reference

12 December 2020

Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice.

1 reference

12 December 2020

Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2).

1 reference

12 December 2020

Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin

1 reference

12 December 2020

Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.

1 reference

12 December 2020

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan

1 reference

12 December 2020

Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan

1 reference

12 December 2020

Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule

1 reference

12 December 2020

The role of half-transporters in multidrug resistance

1 reference

12 December 2020

A multidrug resistance transporter from human MCF-7 breast cancer cells

1 reference

12 December 2020

Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines

1 reference

12 December 2020

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

1 reference

12 December 2020

Irinotecan pathway genotype analysis to predict pharmacokinetics

1 reference

12 December 2020

Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors

1 reference

12 December 2020

ABC transporters and inhibitors: new targets, new agents.

1 reference

12 December 2020

The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s)

1 reference

12 December 2020

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors

1 reference

12 December 2020

The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane

1 reference

12 December 2020

Score tests for association between traits and haplotypes when linkage phase is ambiguous

1 reference

12 December 2020

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition

1 reference

12 December 2020

Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.

1 reference

12 December 2020

Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.

1 reference

12 December 2020

The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human hematopoietic and other cells

1 reference

12 December 2020

Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue

1 reference

12 December 2020

Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes

1 reference

12 December 2020

Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors

1 reference

12 December 2020

A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors

1 reference

12 December 2020

10.1007/S10637-006-6335-5

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

16505951

1 reference

26 December 2017